Control of granzymes by serpins

Cell Death and Differentiation

Volumn 17, Issue 4, 2010, Pages 586-595

  Kaiserman, D ^a   Bird, P I ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Granzyme; Serpin

Indexed keywords

GRANZYME B; INTERLEUKIN 1BETA CONVERTING ENZYME; SERINE PROTEINASE INHIBITOR; SERPINA1; SERPINB9; SERPINC1; UNCLASSIFIED DRUG;

CELL DAMAGE; CELL PROTECTION; CLADISTICS; COMPLEMENT CLASSICAL PATHWAY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME RELEASE; ENZYME SPECIFICITY; ENZYME STRUCTURE; EXTRACELLULAR SPACE; HUMAN; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION;

ANIMALS; CYTOPROTECTION; GRANZYMES; HUMANS; IMMUNE SYSTEM; MEMBRANE PROTEINS; MICE; SERINE ENDOPEPTIDASES; SERPINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

RODENTIA;

EID: 77949500554     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.169     Document Type: Review

References (104)

1. Irving JA, Pike RN, Lesk AM, Whisstock JC. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
2. Irving JA, Steenbakkers PJ, Lesk AM, Op den Camp HJ, Pike RN, Whisstock JC. Serpins in prokaryotes. Mol Biol Evol 2002; 19: 1881-1890.
3. Loebermann H, Tokuoka R, Deisenhofer J, Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177: 531-557.
4. Stein P, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-621.
5. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-162.
6. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 1983; 309: 694-698.
7. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-25312.
8. Stratikos E, Gettins PG. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A. Proc Natl Acad Sci USA 1999; 96: 4808-4813.
9. Wilczynska M, Fa M, Ohlsson PI, Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270: 29652-29655.
10. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
11. Travis J, Salvesen G. Control of coagulation and fibrinolysis by plasma proteinase inhibitors. Behring Inst Mitt 1983; 73: 56-65.
12. Pike RN, Buckle AM, le Bonniec BF, Church FC. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J 2005; 272: 4842-4851.
13. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
14. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273.
15. Belorgey D, Crowther DC, Mahadeva R, Lomas DA. Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002; 277: 17367-17373.
16. Bottomley SP, Hopkins PC, Whisstock JC. Alpha 1-antitrypsin polymerisation can occur by both loop A and C sheet mechanisms. Biochem Biophys Res Commun 1998; 251: 1-5.
17. Chang WS, Whisstock J, Hopkins PC, Lesk AM, Carrell RW, Wardell MR. Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins. Protein Sci 1997; 6: 89-98.
18. Remold-O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett 1993; 315: 105-108.
19. Silverman GA, Whisstock JC, Askew DJ, Pak SC, Luke CJ, Cataltepe S et al. Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell Mol Life Sci 2004; 61: 301-325.
20. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809.
21. Buzza MS, Hirst CE, Bird CH, Hosking P, McKendrick J, Bird PI. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell Immunol 2001; 210: 21-29.
22. Hirst CE, Buzza MS, Sutton VR, Trapani JA, Loveland KL, Bird PI. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. Mol Hum Reprod 2001; 7: 1133-1142.
23. Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 2001; 166: 3218-3225.
24. Hirst CE, Buzza MS, Bird CH, Warren HS, Cameron PU, Zhang M et al. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003; 170: 805-815.
25. Trapani JA, Klein JL, White PC, Dupont B. Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes. Proc Natl Acad Sci USA 1988; 85: 6924-6928.
26. Kim WJ, Kim H, Suk K, Lee WH. Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis. Immunol Lett 2007; 111: 57-65.
27. Strik MC, de Koning PJ, Kleijmeer MJ, Bladergroen BA, Wolbink AM, Griffith JM et al. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol 2007; 44: 3462-3472.
28. Tschopp CM, Spiegl N, Didichenko S, Lutmann W, Julius P, Virchow JC et al. Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma. Blood 2006; 108: 2290-2299.
29. Wagner C, Iking-Konert C, Denefleh B, Stegmaier S, Hug F, Hansch GM. Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils. Blood 2004; 103: 1099-1104.
30. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104: 2840-2848.
31. Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009; 183: 1838-1845.
32. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B et al. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 2002; 100: 3295-3303.
33. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced qcell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 2006; 176: 97-110.
34. Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Titeux M, Tonasso L et al. Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin. J Biol Chem 2006; 281: 13525-13532.
35. Horiuchi K, Saito S, Sasaki R, Tomatsu T, Toyama Y. Expression of granzyme B in human articular chondrocytes. J Rheumatol 2003; 30: 1799-1810.
36. Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJ. Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 2004; 66: 1417-1422.
37. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232-237.
38. Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109: 2183-2189.
39. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA et al. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 2007; 13: 206-214.
40. Godal R, Keilholz U, Uharek L, Letsch A, Asemissen AM, Busse A et al. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood 2006; 107: 3205-3211.
41. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-4546.
42. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11: 6400-6407.
43. Mahrus S, Kisiel W, Craik CS. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 2004; 279: 54275-54282.
44. Bird PI. Serpins and regulation of cell death. Results Probl Cell Differ 1998; 24: 63-89.
45. Bird CH, Blink EJ, Hirst CE, Buzza MS, Steele PM, Sun J et al. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol Cell Biol 2001; 21: 5396-5407.
46. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387-6398.
47. Ida H, Nakashima T, Kedersha NL, Yamasaki S, Huang M, Izumi Y et al. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol 2003; 33: 3284-3292.
48. Laforge M, Bidere N, Carmona S, Devocelle A, Charpentier B, Senik A. Apoptotic death concurrent with CD3 stimulation in primary human CD8+ T lymphocytes: a role for endogenous granzyme B. J Immunol 2006; 176: 3966-3977.
49. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996; 271: 29073-29079.
50. Ko YH, Park S, Jin H, Woo H, Lee H, Park C et al. Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma. Lab Invest 2007; 87: 241-250.
51. Benning LN, Whisstock JC, Sun J, Bird PI, Bottomley SP. The human serpin protein-ase inhibitor-9 self-associates at physiological temperatures. Protein Sci 2004; 13: 1859-1864.
52. Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, Glaser C et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182: 6815-6823.
53. Berthou C, Marolleau JP, Lafaurie C, Soulie A, Dal Cortivo L, Bourge JF et al. Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 1995; 86: 3500-3506.
54. Bladergroen BA, Strik MC, Wolbink AM, Wouters D, Broekhuizen R, Kummer JA et al. The granzyme B inhibitor proteinase inhibitor 9 (PI9) is expressed by human mast cells. Eur J Immunol 2005; 35: 1175-1183.
55. Kannan-Thulasiraman P, Shapiro DJ. Modulators of inflammation use nuclear qfactor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J Biol Chem 2002; 277: 41230-41239.
56. Classen CF, Bird PI, Debatin KM. Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol 2006; 143: 534-542.
57. Barrie MB, Stout HW, Abougergi MS, Miller BC, Thiele DL. Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6. J Immunol 2004; 172: 6453-6459.
58. Stennicke HR, Renatus M, Meldal M, Salvesen GS. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 2000; 350 (Part 2): 563-568.
59. Annand RR, Dahlen JR, Sprecher CA, De Dreu P, Foster DC, Mankovich JA et al. Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem J 1999; 342 (Part 3): 655-665.
60. Young JL, Sukhova GK, Foster D, Kisiel W, Libby P, Schonbeck U. The serpin pro-teinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med 2000; 191: 1535-1544.
61. Kummer JA, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R et al. Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ 2007; 14: 1486-1496.
62. Buzza MS, Bird PI. Extracellular granzymes: current perspectives. Biol Chem 2006; 387: 827-837.
63. Buzza MS, Dyson JM, Choi H, Gardiner EE, Andrews RK, Kaiserman D et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J Biol Chem 2008; 283: 22498-22504.
64. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005; 280: 23549-23558.
65. Choy JC, Hung VH, Hunter AL, Cheung PK, Motyka B, Goping IS et al. Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol 2004; 24: 2245-2250.
66. Prakash MD, Bird CH, Bird PI. Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement. Immunol Cell Biol 2009; 87: 249-254.
67. Froelich CJ, Zhang X, Turbov J, Hudig D, Winkler U, Hanna WL. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 1993; 151: 7161-7171.
68. Chamberlain CM, Granville DJ. The role of Granzyme B in atheromatous diseases. Can J Physiol Pharmacol 2007; 85: 89-95.
69. Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem 1991; 266: 98-103.
70. Tremblay GM, Wolbink AM, Cormier Y, Hack CE. Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors. J Immunol 2000; 165: 3966-3969.
71. Rowshani AT, Strik MC, Molenaar R, Yong SL, Wolbink AM, Bemelman FJ et al. The granzyme B inhibitor SERPINB9 (protease inhibitor 9) circulates in blood and increases on primary cytomegalovirus infection after renal transplantation. J Infect Dis 2005; 192: 1908-1911.
72. Scott FL, Coughlin PB, Bird C, Cerruti L, Hayman JA, Bird P. Proteinase inhibitor 6 cannot be secreted, which suggests it is a new type of cellular serpin. J Biol Chem 1996; 271: 1605-1612.
73. Coughlin P, Sun J, Cerruti L, Salem HH, Bird P. Cloning and molecular characterization of a human intracellular serine proteinase inhibitor. Proc Natl Acad Sci USA 1993; 90: 9417-9421.
74. Remold-O'Donnell E, Chin J, Alberts M. Sequence and molecular characterization of human monocyte/neutrophil elastase inhibitor. Proc Natl Acad Sci USA 1992; 89: 5635-5639.
75. Sipione S, Simmen KC, Lord SJ, Motyka B, Ewen C, Shostak I et al. Identification of a novel human granzyme B inhibitor secreted by cultured sertoli cells. J Immunol 2006; 177: 5051-5058.
76. Casciola-Rosen L, Garcia-Calvo M, Bull HG, Becker JW, Hines T, Thornberry NA et al. Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem 2007; 282: 4545-4552.
77. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol 2006; 175: 619-630.
78. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98: 11515-11520.
79. Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001; 194: 657-667.
80. Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF et al. Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol 2008; 181: 8356-8362.
81. Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE et al. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 2006; 24: 451-461.
82. Masson D, Tschopp J. Inhibition of lymphocyte protease granzyme A by antithrombin III. Mol Immunol 1988; 25: 1283-1289.
83. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13: 363-368.
84. Huntington JA, Olson ST, Fan B, Gettins PG. Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry 1996; 35: 8495-8503.
85. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-609.
86. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 1982; 257: 14891-14895.
87. Spaeny-Dekking EH, Kamp AM, Froelich CJ, Hack CE. Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors. Blood 2000; 95: 1465-1472.
88. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4: 544-558.
89. Kaiserman D, Knaggs S, Scarff KL, Gillard A, Mirza G, Cadman M et al. Comparison of human chromosome 6p25 with mouse chromosome 13 reveals a greatly expanded ov-serpin gene repertoire in the mouse. Genomics 2002; 79: 349-362.
90. Askew DJ, Askew YS, Kato Y, Turner RF, Dewar K, Lehoczky J et al. Comparative genomic analysis of the clade B serpin cluster at human chromosome 18q21: amplification within the mouse squamous cell carcinoma antigen gene locus. Genomics 2004; 84: 176-184.
91. Kaiserman D, Buckle AM, Van Damme P, Irving JA, Law RH, Matthews AY et al. Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. Proc Natl Acad Sci USA 2009; 106: 5587-5592.
92. Odake S, Kam CM, Narasimhan L, Poe M, Blake JT, Krahenbuhl O et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 1991; 30: 2217-2227.
93. Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 2005; 12: 567-577.
94. Bots M, Kolfschoten IG, Bres SA, Rademaker MT, De Roo GM, Kruse M et al. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 2005; 105: 1153-1161.
95. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 2008; 29: 720-733.
96. Quan LT, Caputo A, Bleackley RC, Pickup DJ, Salvesen GS. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J Biol Chem 1995; 270: 10377-10379.
97. Zhou A, Carrell RW, Huntington JA. The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem 2001; 276: 27541-27547.
98. Fujino M, Kawasaki M, Funeshima N, Kitazawa Y, Kosuga M, Okabe K et al. CrmA gene expression protects mice against concanavalin-A-induced hepatitis by inhibiting IL-18 secretion and hepatocyte apoptosis. Gene Therapy 2003; 10: 1781-1790.
99. Turner PC, Sancho MC, Thoennes SR, Caputo A, Bleackley RC, Moyer RW. Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta- converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells. J Virol 1999; 73: 6394-6404.
100. MacNeill AL, Turner PC, Moyer RW. Mutation of the Myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology 2006; 356: 12-22.
101. Nathaniel R, MacNeill AL, Wang YX, Turner PC, Moyer RW. Cowpox virus CrmA, Myxoma virus SERP2 and baculovirus P35 are not functionally interchangeable caspase inhibitors in poxvirus infections. J Gen Virol 2004; 85 (Part 5): 1267-1278.
102. Pak SC, Kumar V, Tsu C, Luke CJ, Askew YS, Askew DJ et al. SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenor-habditis elegans: initial characterization of the clade L serpins. J Biol Chem 2004; 279: 15448-15459.
103. Dahlen JR, Foster DC, Kisiel W. Human proteinase inhibitor 9 (PI9) is a potent inhibitor of subtilisin A. Biochem Biophys Res Commun 1997; 238: 329-333.
104. Kaiserman D, Whisstock JC, Bird PI. Mechanisms of serpin dysfunction in disease. Expert Rev Mol Med 2006; 8: 1-19.